From Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine

Overview

Journal J Pers Med

Date 2022 Jun 24

PMID 35743678

Authors

Laura Maintz

Thomas Bieber

Helen D Simpson

Anne-Laure Demessant-Flavigny

Affiliations

Soon will be listed here.

Abstract

Atopic dermatitis (AD) affects up to 20% of children and is considered the starting point of the atopic march with the development of food allergy, asthma, and allergic rhinitis. The heterogeneous phenotype reflects distinct and/or overlapping pathogenetic mechanisms with varying degrees of epidermal barrier disruption, activation of different T cell subsets and dysbiosis of the skin microbiome. Here, we review current evidence suggesting a systemic impact of the cutaneous inflammation in AD together with a higher risk of asthma and other comorbidities, especially in severe and persistent AD. Thus, early therapy of AD to restore the impaired skin barrier, modified microbiome, and target type 2 inflammation, depending on the (endo)phenotype, in a tailored approach is crucial. We discuss what we can learn from the comorbidities and the implications for preventive and therapeutic interventions from precision dermocosmetics to precision medicine. The stratification of AD patients into biomarker-based endotypes for a precision medicine approach offers opportunities for better long-term control of AD with the potential to reduce the systemic impact of a chronic skin inflammation and even prevent or modify the course, not only of AD, but possibly also the comorbidities, depending on the patient's age and disease stage.

Citing Articles

Soothing the Itch: The Role of Medicinal Plants in Alleviating Pruritus in Palliative Care.

Goncalves S, Fernandes L, Caramelo A, Martins M, Rodrigues T, Matos R Plants (Basel). 2025; 13(24.

PMID: 39771213 PMC: 11677410. DOI: 10.3390/plants13243515.

Advanced Systemic Treatments in Patients with Moderate-to-Severe Atopic Dermatitis: Key Learnings from Physicians Practicing in Nine Asian Countries and Territories.

Chu C, Bhat Marne R, Cheung C, Diep L, Noppakun N, Novianto E Dermatol Ther (Heidelb). 2024; 14(10):2669-2691.

PMID: 39340696 PMC: 11480307. DOI: 10.1007/s13555-024-01278-x.

Primary Prevention of Canine Atopic Dermatitis: Breaking the Cycle-A Narrative Review.

Fernandes B, Alves S, Schmidt V, Bizarro A, Pinto M, Pereira H Vet Sci. 2023; 10(11).

PMID: 37999481 PMC: 10674681. DOI: 10.3390/vetsci10110659.

Emollients "Plus" are Beneficial in Both the Short and Long Term in Mild Atopic Dermatitis.

Cestari S, Correia P, Kerob D Clin Cosmet Investig Dermatol. 2023; 16:2093-2102.

PMID: 37575149 PMC: 10422989. DOI: 10.2147/CCID.S417622.

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.

Kolkhir P, Akdis C, Akdis M, Bachert C, Bieber T, Canonica G Nat Rev Drug Discov. 2023; 22(9):743-767.

PMID: 37528191 DOI: 10.1038/s41573-023-00750-1.

References

Kelleher M, Cro S, Van Vogt E, Cornelius V, Carlsen K, Skjerven H . Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data meta-analysis. Clin Exp Allergy. 2021; 51(3):402-418. DOI: 10.1111/cea.13847. View

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32(5):657-682. DOI: 10.1111/jdv.14891. View

Liezmann C, Klapp B, Peters E . Stress, atopy and allergy: A re-evaluation from a psychoneuroimmunologic persepective. Dermatoendocrinol. 2011; 3(1):37-40. PMC: 3051852. DOI: 10.4161/derm.3.1.14618. View

Rogers A, Celedon J, Lasky-Su J, Weiss S, Raby B . Filaggrin mutations confer susceptibility to atopic dermatitis but not to asthma. J Allergy Clin Immunol. 2007; 120(6):1332-7. DOI: 10.1016/j.jaci.2007.09.037. View

Castro-Rodriguez J, Holberg C, Wright A, Martinez F . A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000; 162(4 Pt 1):1403-6. DOI: 10.1164/ajrccm.162.4.9912111. View

van Halewijn K, Lahnstein T, Bohnen A, van den Berg P, Pasmans S, Bindels P . Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines. Eur J Dermatol. 2022; 32(1):113-123. DOI: 10.1684/ejd.2022.4197. View

Silverwood R, Forbes H, Abuabara K, Ascott A, Schmidt M, Schmidt S . Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018; 361:k1786. PMC: 6190010. DOI: 10.1136/bmj.k1786. View

Suarez-Farinas M, Tintle S, Shemer A, Chiricozzi A, Nograles K, Cardinale I . Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011; 127(4):954-64.e1-4. PMC: 3128983. DOI: 10.1016/j.jaci.2010.12.1124. View

Chalmers J, Haines R, Bradshaw L, Montgomery A, Thomas K, Brown S . Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet. 2020; 395(10228):962-972. PMC: 7086156. DOI: 10.1016/S0140-6736(19)32984-8. View

10.

Akdis C . Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?. Nat Rev Immunol. 2021; 21(11):739-751. DOI: 10.1038/s41577-021-00538-7. View

11.

Hill D, Spergel J . The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018; 120(2):131-137. PMC: 5806141. DOI: 10.1016/j.anai.2017.10.037. View

12.

Bakker D, de Graaf M, Nierkens S, Delemarre E, Knol E, van Wijk F . Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters. J Allergy Clin Immunol. 2021; 149(1):125-134. DOI: 10.1016/j.jaci.2021.06.029. View

13.

Liu F, Goodarzi H, Chen H . IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol. 2011; 41(3):298-310. DOI: 10.1007/s12016-011-8252-4. View

14.

Hammad H, Lambrecht B . Barrier Epithelial Cells and the Control of Type 2 Immunity. Immunity. 2015; 43(1):29-40. DOI: 10.1016/j.immuni.2015.07.007. View

15.

Czarnowicki T, He H, Canter T, Han J, Lefferdink R, Erickson T . Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2019; 145(1):215-228. PMC: 6957229. DOI: 10.1016/j.jaci.2019.09.031. View

16.

Lowe A, Su J, Tang M, Lodge C, Matheson M, Allen K . PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open. 2019; 9(3):e024594. PMC: 6430027. DOI: 10.1136/bmjopen-2018-024594. View

17.

Li H, Dai T, Liu C, Liu Q, Tan C . Phenotypes of atopic dermatitis and the risk for subsequent asthma: A systematic review and meta-analysis. J Am Acad Dermatol. 2021; 86(2):365-372. DOI: 10.1016/j.jaad.2021.07.064. View

18.

Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C . Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009; 206(5):1135-47. PMC: 2715042. DOI: 10.1084/jem.20082242. View

19.

Gallagher A, Edwards M, Nair P, Drew S, Vyas A, Sharma R . Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. Cochrane Database Syst Rev. 2021; 10:CD012929. PMC: 8524317. DOI: 10.1002/14651858.CD012929.pub2. View

20.

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018; 32(6):850-878. DOI: 10.1111/jdv.14888. View